Healthcare-associated Infections
Figure 3: Effectiveness of the Dry-mist Hydrogen Peroxide Process in Real-use Conditions After One Cycle in Several Hospital Centres
Infectious Diseases Laboratory
Endoscopy Reanimation
Haemodialysis
0 2
OR 0 1
OR 4 0 200 400 600 800 1,000 1,200 1,400 1,600
20 CFU before CFU = colony-forming unit; OR = operating room.
Results of the test confirmed a log reduction greater than five. The researchers confirmed the efficiency of the GLOSAIR process during an outbreak at the University Hospital in Toulouse, France.
Evidence suggests that GLOSAIR is also effective at preventing infections in healthcare facilities when included as part of an integrated infection prevention programme. “After introducing the area decontamination solution GLOSAIR™, now provided by Advanced Sterilization Products (ASP), as a part of our infection prevention
1. Healthcare-associated Infections (HCAI). European Centre for Disease Prevention and Control website. Available at:
http://ecdc.europa.eu/en/healthtopics/ Healthcare-associated_infections/Pages/
index.aspx (accessed 1 August 2011).
2. Falagas M, Thomaidis P, Kotsantis I, et al., Airborne hydrogen peroxide for disinfection of the hospital environment and infection control: a systematic review, J Hosp Infect, 2011;78(3):171–7.
3. Marty N, Cavalié L, Conil J, Roques C, Dry fog disinfection: an assessment of microbiological efficacy and practical advantages, Revue Hygienes, 2007;15:317–20.
4. Europa: The Official Website of the European Union, Questions and Answers on Patient Safety, Including the Prevention and Control of Healthcare Associated Infections, available from:
http://europa.eu/rapid/pressReleasesAction. do?reference=MEMO/08/788&format=HTML&aged= 0&language=EN (accessed 17 July 2011.
5. Data on file. Available (with permission) at:
www.aspjj.com/ emea/about/contact_me (accessed 30 August 2011).
6. Vrijens F, Hulstaert F, Van de Sande S, et al., Hospital- acquired, laboratory-confirmed bloodstream infections: linking national surveillance data to clinical and financial hospital data to estimate increased length of stay and healthcare costs, J Hosp Infect, 2010;75:158–62. 7. Resch A, Wilke M, Fink C, The cost of resistance:
CFU after
4 4
720 250 300 450 1,500 1,000
Diane Wake, Director of Infection Prevention and Control at the Royal Liverpool University Hospital, says: “We have halved our C. difficile rates in the last year. With a greater emphasis on cleaning and cleaning standards, and the use of innovative solutions, as provided by ASP, we have made tackling hospital infections our top priority… We have gone from being one of the poorest to one of the best-performing trusts in the country for infection control.”
“Many places in the haemodialysis room and other rooms are very hard to reach. After the study, we found that the heater grills in the patient rooms were highly infected; despite traditional manual cleaning efforts. GLOSAIR was able to bring the pathogen numbers down to zero,” states Dr Graça Pombo, Laboratory and Infection Control Director at the Centro Hospitalar Do Nordeste, Unidade Hospitalar de Bragança, Portugal.
Patients rightly expect hospitals to be pathogen free in order to deliver care that does not expose them to unnecessary risk. Innovations such as the GLOSAIR Area Decontamination System, when used as part of a proactive, infection prevention programme, are helping hospitals to effectively reduce bioburden and safeguard patient health. n
incremental cost of methicillin-resistant Stayphylococcus aureus (MRSA) in German hospitals, Eur J Health Econ, 2009;10(3):287–97.
8. ASP data on file. Original calculation in USD converted to Euros: 1 USD = 0.69 €.
9. Ploughman R, Graves N, Griffin M, et al., The Socio-Economic Burden of Hospital Acquired Infection, Public Health Laboratory Service – Report for the Department of Health, 1999.
10. European Centre for Disease Prevention and Control, Healthcare-associated infections. Available from:
http://ecdc.europa.eu/en/healthtopics/healthcare- associated_infections/pages/
index.aspx (accessed 17 July 2011).
11. Carling PC, Parry MF, Von Beheren SM, Identifying Opportunities to Enhance Environmental Cleaning in 23 Acute Care Hospitals, ICHE, 2008;29(1):1–7.
12. Gannon PF, Bright P, Campbell M, et al., Occupational asthma due to glutaraldehyde and formaldehyde in endoscopy and X-ray departments, Thorax, 1995;50:156–9.
13. ASP, data on file. 14. ASP, GLOSAIR™ 400 System. Available from:
www.aspjj.com/ emea/products/area-decontamination/glosair-400-system (accessed 17 July 2011).
15. ASP Field Trial, Dry-mist of hydrogen peroxide compares favourably with manual cleaning with ammonia for decontamination of hospital rooms, Johnson & Johnson, 2010.
16. Barbut F, Menuet D, Verachten M, Girou E, Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of Clostridium difficile spores, Infect Control Hosp Epidemiol, 2009;30(6):507–14.
17. Shapey S, Machin K, Levi K, Boswell TC, Activity of a dry mist hydrogen peroxide system against environmental Clostridium difficile contamination in elderly care wards, J Hosp Infect, 2008;70(2):131–41.
18. Andersen B, Rasch M, Hochlin K, et al., Decontamination of rooms, medical equipment and ambulances using an aerosol of hydrogen peroxide disinfectant, J Hosp Infect, 2006;62:149–55.
19. Grare M, Dailloux M, Simon L, et al., Efficacy of dry mist of hydrogen peroxide (DMHP) against Mycobacterium tuberculosis and use of DMHP for routine decontamination of biosafety level 3 laboratories, J Clin Microbiol, 2008;46(9):2955–8.
20. Bartels D, Kristoffersen K, Slotsbjerg T, et al., Environmental methicillin-resistant Staphylococcus aureus (MRSA) disinfection using dry-mist generated hydrogen peroxide, J Hosp Infect, 2008;70:35–41.
21. Roques C, Improvement of vancomycin-resistant enterococci eradication in hospitals by combined barrier precautions and disinfection using an automatic dry mist system, European Infectious Disease, 2010;4: 63–5.
programme, our C. difficile cases were reduced by 62 % over a period of 12 months, and this reduction was sustained over the following 24 months,” says Dr Boswell, Consultant Medical Microbiologist at Nottingham University Hospitals.
120
EUROPEAN INFECTIOUS DISEASE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92